Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PBX0 | ISIN: US22304C1009 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
COVETRUS INC Chart 1 Jahr
PR Newswire
354 Leser
Artikel bewerten:
(2)

Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus

Finanznachrichten News

Revolutionary haemostatic gel for veterinary surgeons available in UK and across Europe through Veterinary Instrumentation and distribution partners

NEW YORK, May 20, 2024 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly to veterinary surgeons in the UK and throughout Europe through Veterinary Instrumentation (Vi), a leading supplier of professional products to support veterinarians in maintaining animal welfare during surgery.

Cresilon, Inc. (PRNewsfoto/Cresilon)

Based in the UK, Vi is part of the Covetrus animal health family of worldwide businesses. Cresilon's VETIGEL, a plant-based haemostatic gel that instantly stops and controls bleeding, is available online for UK veterinary surgeons through Vi's extensive portfolio of surgical and orthopaedic instrumentation, joint surgery, and fracture fixation products.

In addition to the UK, VETIGEL will be marketed and distributed to veterinary surgeons throughout Europe and many other countries through Vi's extensive global distribution network. Cresilon's Scientific Services Veterinarian and Fellow of the Royal College of Veterinary Surgeons (FRCVS), Dr. Neil Smith, will be providing online training on VETIGEL to all Vi distribution partners in June.

"Our partnership with Veterinary Instrumentation will help us provide more veterinary surgeons with a revolutionary haemostatic gel that significantly improves the standard of care for pets and animals," said Matt Lewis, Vice President of Sales at Cresilon. "VETIGEL has been used by thousands of veterinarians thus far and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes."

Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most effective haemostatic agent when treating animals for traumatic wounds and routine and complex surgical procedures, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations. To date, the plant-based haemostatic gel for veterinary surgeons has been used in more than 50,000 surgical procedures worldwide.

VETIGEL offers veterinary surgeons a safe and efficient way to control animal bleeding across multiple types of bleeds and a wide range of surgical procedures. The veterinary haemostatic agent is made of two plant-based polysaccharides that form an instant mechanical barrier to stop bleeding on contact. Once the bleeding is controlled, VETIGEL can be easily removed without disturbing the underlying clot or left in the body to resorb.

The plant-based haemostatic gel is supplied in a pre-filled syringe, is easy-to-use, and requires no preparation or special storage conditions. For more information about VETIGEL, visit www.vetigel.co.uk.

About Cresilon
Cresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets haemostatic medical devices utilising the company's proprietary hydrogel technology. The company's plant-based technology has revolutionised the current standard by stopping bleeding in seconds. The company's current and future product lines target veterinary, human trauma, and human surgical applications. Cresilon's mission is to save lives. For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit www.cresilon.com.

Logo - https://mma.prnewswire.com/media/1699548/Cresilon_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/cresilon-announces-international-distribution-agreement-for-vetigel-with-covetrus-302149478.html

© 2024 PR Newswire
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.